FIELD: biotechnologies.
SUBSTANCE: present invention refers to biotechnology. Disclosed is a conjugate for targeted delivery of a therapeutic polypeptide in vivo containing a bispecific antibody and a haptenylated therapeutic polypeptide, where the bispecific antibody contains a first binding site which specifically binds to the hapten, and a second binding site that specifically binds to a cell surface cell marker, wherein the first antibody site is covalently bonded to the hapten using a cysteine residue at position 52b or 53 in the heavy chain CDR2 according to Cabot numbering, and wherein the hapten is selected from a group consisting of biotin, digoxigenin, theophylline and fluorescein.
EFFECT: covalent bond with hapten provides stabilization of therapeutic polypeptide; in this regard, the present invention can find application in therapy.
4 cl, 46 dwg, 24 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | 2014 |
|
RU2693438C2 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
| COVALENTLY LINKED CONJUGATES CHELICAR-ANTIBODY AGAINST CHELICAR AND USE THEREOF | 2014 |
|
RU2694981C2 |
| ANTIBODIES TO BIOTIN AND APPLICATION METHODS | 2013 |
|
RU2630296C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| ANTIBODIES AGAINST 5-BROMO-2'-DEOXYURIDINE AND METHODS OF USE | 2015 |
|
RU2705299C2 |
| HAPTEN-CARRIER CONJUGATES AND APPLICATION | 2003 |
|
RU2326693C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| NOVEL METHODS OF ENZYME-MEDIATED CONJUGATION OF POLYPEPTIDES USING SORTASE | 2015 |
|
RU2714963C2 |
| ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
